RxDoctor Payments DataLook up a doctor →

Mitchell Lee, MD

Pulmonary Disease · Wilmington, NCNPI 1053339267

Payments from drug & device makers

$1,494,322in general payments, 2019–2025

Across 765 payments — averaging $1953.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$406K
  • AstraZeneca$343K
  • Boehringer Ingelheim$166K
  • Grifols Therapeutics LLC$127K
  • Chiesi USA, Inc.$91K
  • Bristol Myers Squibb$81K
  • plus $280K from 38 others
$1,393in research payments, 2019–2025

Across 15 payments — averaging $92.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,494,322 in reported general payments places this provider in the 95th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$12,830
Medicare patients
49
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →